anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVE: POLR3B encodes the second largest subunit of RNA polymerase III, which is essential for transcription of small non-coding RNAs. Biallelic pathogenic variants in POLR3B are associated with an inherited hypomyelinating leukodystrophy. Recently, de novo heterozygous variants in POLR3B were reported in six individuals with ataxia, spasticity, and demyelinating peripheral neuropathy. Three of these individuals had epileptic seizures. The aim of this article is to precisely define the epilepsy phenotype associated with de novo heterozygous POLR3B variants.
METHODS: We used online gene-matching tools to identify 13 patients with de novo POLR3B variants. We systematically collected genotype and phenotype data from clinicians using two standardized proformas.
RESULTS: All 13 patients had novel POLR3B variants. Twelve of 13 variants were classified as pathogenic or likely pathogenic as per American College of Medical Genetics (ACMG) criteria. Patients presented with generalized myoclonic, myoclonic-atonic, atypical absence, or tonic-clonic seizures between the ages of six months and 4 years. Epilepsy was classified as epilepsy with myoclonic-atonic seizures (EMAtS) in seven patients and "probable EMAtS" in two more. Seizures were treatment resistant in all cases. Three patients became seizure-free. All patients had some degree of developmental delay or intellectual disability. In most cases developmental delay was apparent before the onset of seizures. Three of 13 cases were reported to have developmental stagnation or regression in association with seizure onset. Treatments for epilepsy that were reported by clinicians to be effective were: sodium valproate, which was effective in five of nine patients (5/9) who tried it; rufinamide (2/3); and ketogenic diet (2/3). Additional features were ataxia/incoordination (8/13); microcephaly (7/13); peripheral neuropathy (4/13), and spasticity/hypertonia (6/13).
SIGNIFICANCE: POLR3B is a novel genetic developmental and epileptic encephalopathy (DEE) in which EMAtS is the predominant epilepsy phenotype. Ataxia, neuropathy, and hypertonia may be variously observed in these patients.
A method and system providing medical treatment to patients. In some embodiments, a patient is granted clinically sufficient access to their underlying health records and is able to observe and place treatment orders. In some embodiments, a patient and a practitioner are able to collaborate on the patient's treatments. In some embodiments, a practitioner is summoned from a pool of practitioners. In some embodiments, a change manager tracks changes to the underlying medical treatment plan for potential review, approval, modification, or rejection. Further embodiments provide a collaboration or supervision interface between patients and automated medical decision or practice systems, such as robodocs.
The present invention relates to a quick acting and heart resurrecting oral disintegrating tablet and a preparation process thereof, which belongs to an oral disintegrating type traditional Chinese medicine preparation containing easily subliming medicinal components and a preparation technology thereof. The problems are solved that an effective constituent, namely borneol is easy to sublime to make medicinal effect content unstable in the process of producing and storing quick acting and heart resurrecting medicines at present, and comatose patients and patients with serious diseases can not take the medicines conveniently. In the present invention, the borneol is prepared into solid microcapsules (ball) or dispersive bodies which are uniformly mixed with szechwan lovage rhizome, a corrective, a bulking agent, a disintegrating agent, a lubricating agent and glidant and then processed through sieving and tabletting so as to obtain the oral disintegrating tablet through a modern package technology. The preparation can be taken conveniently and sufficiently disintegrated without taking water in the mouth cavity, and the operation of disintegration can be completed within 10 to 50 seconds so as to rapidly obtain the effects of efficiently releasing the medicine, rapidly taking effects and early peaking. Accordingly, the oral disintegrating tablet is especially suitable for partial patients with dysphagia or narcose patients to take with conspicuous curative effects. The present invention has the advantages of simple and direct preparation processes, optimized working environment and obtained economic benefit and social benefit.
Patients undergo removal of nearly all of the lymph nodes from the central part of the chest between the lungs, followed by pulmonary resection. Patients are followed at 4, 6, 8, 12, 18, 24, and 36 months and then annually thereafter until death.
Subjects for this study will be adults with type 1 diabetes who use insulin pump in their diabetes self-management. Prior to admission the the clinical research center the basal rates and insulin-to-carbohydrate ratio of the subjects will be optimized using standard clinical procedures.

Subjects will be admitted to the clinical research center in mid-morning following a light breakfast at home. Subjects will have several admissions and, in random order, will receive lunches with identical carbohydrate content but different fat content: lunch A will minimal fat content, lunch B will contain added butter, lunch C will contain added olive oil, and lunch D will contain added cheese. Total fat content in lunches B-D will be the same. Subjects will receive identical insulin doses (calculated using the subject's usual insulin-to-carbohydrate ratio) for the meals. Blood samples for measurement of plasma glucose and insulin levels will be drawn for the subsequent 6 hours. We hypothesize that postprandial glucose levels 3-6 hours after start of the meal will be higher following lunches B and D, compared to lunches A and C.
The present invention provides a computer-implemented method for assessing dental professional posture, a system for carrying out the claimed method. The method comprises receiving, from a sensor, dental procedure plan information. The dental procedure plan information indicates a dental procedure to be carried out by the dental professional. A predicted posture is determined based on the dental procedure plan information. A posture guidance recommendation is generated based on the posture information and the predicted posture. The method further comprises outputting the posture guidance recommendation.
This intervention arm will receive the serious game known as 'Happy Heart'. The game will be installed in their mobile devices through a link. The adolescents in this arm will play the game on their mobiles for 2 weeks.
This is an integrated social norms-based personalized feedback intervention for college students targeting alcohol misuse and sexual assault. It targets alcohol, sexual assault victimization risk, sexual assault perpetration, and bystander intervention. It is tailored by gender and sexual orientation. It is provided at baseline and a booster at 6 months.
Osteoporosis is a widespread disease characterized by the loss of bone mineral density (BMD). 16 Bit has developed an opportunistic screening tool for low BMD, called RhoTM, that analyzes lumbar spine, thoracic spine, chest, pelvis, knee, and hand radiographs, performed in patient age 50 and above for any clinical indication to estimate lumbar and femoral neck BMD. The estimated BMD T-score is used to classify patients as having normal or low BMD. A finding of low BMD can be included in a radiologist's report, and is intended to support a discussion between healthcare provider and patient regarding the need for osteoporosis diagnosis by dual-energy x-ray absorptiometry (DXA). In this way, RhoTM is intended to function as an opportunistic pre-screening device for low BMD. This study seeks to assess the clinical performance and impact of implementing RhoTM in real-world settings by analyzing the diagnostic performance and impact on DXA referrals.
Exercise improves metabolic health and prevents the complications of obesity and type 2 diabetes. The inventors hypothesized that skeletal muscle contraction produces a cellular stress signal triggering adipose tissue lipolysis to sustain fuel availability during exercise. They aimed at identifying novel exercise-regulated exerkines, able to promote lipolysis. Growth and Differentiation Factor 15 (GDF15) gene expression and secretion increased rapidly upon skeletal muscle contraction. GDF15 protein was up-regulated in conditioned media from both acute and chronic exercise-stimulated myotubes. The inventors further show that physiological concentrations of recombinant GDF15 protein increase lipolysis in human adipose tissue. The inventors herein provide the first evidence that GDF15 is a novel exerkine produced by skeletal muscle contraction and able to target human adipose tissue to promote lipolysis. GDF15 could thus be suitable as a marker of exercise management.
Myeloma patients, following up-front induction therapy, will receive an ASCT following a high-dose bendamustine-based preparative regimen (BeEAM). The primary endpoint of this trial will be the rate of CR at day 100 post-transplant. Experience from the literature, as well as results from our institution, suggests that following ASCT for the upfront treatment of myeloma, the rate of CR at day 100 post-transplant is approximately 45%. It is hoped that under this protocol, this rate will be at least 65%. Thus we statistically formalize this study by testing the null hypothesis that p, the CR rate is 0.65 or more versus the alternative hypothesis that p is less than 0.45. A sample size of 65 pts gives 90% power with an alpha=0.05, using the formula for a one sample binomial (two-sided) test of a proportion.
Participants (42-54 months of age) will be assigned to try to open one of three treatments. One cohort will receive a 38/400 bottle equipped with a standard two piece push and turn cap and asked to open this during 2 five minute trials.
CCDC58, a member of the CCDC protein family, has been primarily associated with the malignant progression of hepatocellular carcinoma (HCC) and breast cancer, with limited research conducted on its involvement in other tumor types. We aimed to assess the significance of CCDC58 in pan-cancer. We utilized the TCGA, GTEx, and UALCAN databases to perform the differential expression of CCDC58 at both mRNA and protein levels. Prognostic value was evaluated through univariate Cox regression and Kaplan-Meier methods. Mutation and methylation analyses were conducted using the cBioPortal and SMART databases. We identified genes interacting with and correlated to CCDC58 through STRING and GEPIA2, respectively. Subsequently, we performed GO and KEGG enrichment analyses. To gain insights into the functional status of CCDC58 at the single-cell level, we utilized CancerSEA. We explored the correlation between CCDC58 and immune infiltration as well as immunotherapy using the ESTIMATE package, TIMER2.0, TISIDB, TIDE, TIMSO, and TCIA. We examined the relationship between CCDC58 and tumor heterogeneity, stemness, DNA methyltransferases, and MMR genes. Lastly, we constructed a nomogram based on CCDC58 in HCC and investigated its association with drug sensitivity. CCDC58 expression was significantly upregulated and correlated with poor prognosis across various tumor types. The mutation frequency of CCDC58 was found to be increased in 25 tumors. We observed a negative correlation between CCDC58 expression and the methylation sites in the majority of tumors. CCDC58 showed negative correlations with immune and stromal scores, as well as with NK T cells, Tregs, CAFs, endothelial cells, and immunomodulators. Its value in immunotherapy was comparable to that of tumor mutational burden. CCDC58 exhibited positive correlations with tumor heterogeneity, stemness, DNA methyltransferase genes, and MMR genes. In HCC, CCDC58 was identified as an independent risk factor and demonstrated potential associations with multiple drugs. CCDC58 demonstrates significant clinical value as a prognostic marker and indicator of immune response across various tumor types. Its comprehensive analysis provides insights into its potential implications in pan-cancer research.
This study aimed to investigate the levels of serum, gingival crevicular fluid (GCF), and salivary adipokines and their possible relationship with periodontitis and obesity. An electronic search was conducted in the following databases: PubMed/ Medline, Scopus, and EBSCOhost through February 2023. Two independent reviewers screened the titles, abstracts, and full text of all the studies. Studies comparing the levels of adipokines in GCF, serum, and/or saliva in subjects with obesity and periodontitis (group 1), subjects with normal weight and periodontitis (group 2), and subjects with obesity and gingival health (group 3) were included. Meta-analyses and meta-regression were performed on the data from included studies. Seventeen studies with study participants ranging from 30 to 120 were included with subjects in each group ranging from 10 to 40. There was a significant increase in levels of serum TNF-α, leptin, IL-6, and CRP between groups 1 and 2 (p < .05). In GCF, TNF-α and resistin levels were significantly higher (p < .05) in Group 1 vs. 2. Serum level of leptin was higher for group 1 vs. 3 (p < .05). Meta-regression analysis revealed that the obesity definition (body mass index (BMI) cut-off value >25 or >30) was significant for serum resistin (p < .05) and GCF resistin (p < .05) between group 1 and 2. The current analysis indicates that both periodontitis and obesity can modulate the pro-inflammatory cytokines at systemic and local levels. This bidirectional interaction of periodontitis and obesity via the inflammation pathway seems likely plausible. Further studies are required to elucidate this mechanism in more detail.
In the National Heart, Lung and Blood Institute's Cardiac Arrhythmia Suppression Trial (CAST), a long-term, multi-centered, randomized, double-blind study in patients with asymptomatic non-life-threatening ventricular arrhythmias who had had myocardial infarctions more than six days but less than two years previously, an excessive mortality or non-fatal cardiac arrest rate was seen in patients treated with encainide or flecainide (56/730) compared with that seen in patients assigned to matched placebo-treated groups (22/725). The average duration of treatment with encainide or flecainide in this study was ten months.

Amiodarone therapy was evaluated in two multi-centered, randomized, double-blind, placebo-controlled trials involving 1202 (Canadian Amiodarone Myocardial Infarction Arrhythmia Trial; CAMIAT) and 1486 (European Myocardial Infarction Amiodarone Trial; EMIAT) post-MI patients followed for up to 2 years. Patients in CAMIAT qualified with ventricular arrhythmias, and those randomized to amiodarone received weight- and response-adjusted doses of 200 to 400 mg/day. Patients in EMIAT qualified with ejection fraction <40%, and those randomized to amiodarone received fixed doses of 200 mg/day. Both studies had weeks-long loading dose schedules. Intent-to-treat all-cause mortality results were as follows:

These data are consistent with the results of a pooled analysis of smaller, controlled studies involving patients with structural heart disease (including myocardial infarction).
The invention relates to a plant functional beverage capable of improving immunity and relieving weariness. The plant functional beverage consists of epimedium, eucommia ulmoide leaves, hairyvein agrimonia herb, Chinese dates, tasselblower, white sugar, brown sugar, honey and stevioside. The formula has the efficacies of tonifying the liver and kidney, nourishing yin, strengthening yang, strengthening body, strengthening the body resistance, alleviating deficiency, improving immunity, resisting weariness, relieving physical strength and pressure, and prolonging life. The functional beverage is beneficial to human bodies and has zero toxic or side effect after being drunk for a long term, the immunity can be improved, the physical strength weariness can be relieved, the human bodies are strengthened, and the level of health is increased. A modern health care beverage which is suitable for Chinese is developed, so that the physical constitution of Chinese is improved; Chinese herbal medicine health care products are aligned with the world, so that mankind is benefited. The beverage generates great social benefits and economic benefits to society and human beings through modern industrial production.
INTRODUCTION: C-reactive protein (CRP) is a systemic inflammatory marker, which indicates systemic inflammatory processes It is involved in different inflammatory processes of the body and is a reliable marker for the general inflammatory state of the body. High sensitive CRP seems to play a key role as a state and trait marker of bipolar disorder (BD). In the current study, we tried to determine the long-term effect of CRP levels on clinical symptoms and illness course of bipolar disorder.
METHODS: For the current study, we examined 106 patients with BD for a period of four years. Participants underwent a clinical screening for depressive and manic episodes with the Hamilton Depression Scale (HAMD) and the Young Mania Rating Score (YMRS) and a serological diagnostic for inflammatory parameters every six months, thus leading to 8 measurement times in total. Patients with the presence of severe medical or neurological comorbidities such as active cancer, chronic obstructive lung disease, rheumatoid arthritis, systemic lupus erythematosus, Alzheimer's disease, Parkinson's disease, Huntington's disease or multiple sclerosis and acute infections were not included in the study.
RESULTS: In our sample, 26% showed a mean hsCRP above 5 mg/dl. Those patients showed a significantly higher mean YMRS score than those with a mean hsCRP under 5 mg/dl during our observation period. Regarding HAMD there was no significant difference in hsCRP values. The existence of lithium treatment showed no significant influence on mean hsCRP levels between the start and endpoint.
CONCLUSION: Individuals who were exposed to a higher level of inflammation over time suffered from more manic symptoms in this period. These findings underline the hypothesis that inflammatory processes have an accumulative influence on the illness course of BD, especially concerning manic symptoms and episodes.
Fibrosis is a common manifestation of most progressive and degenerative diseases, with myofibroblast activation and matrix accumulation playing a key role. In this issue of the JCI, Hoeft et al. identify the important role of ADAMTS12 in fibroblast activation. ADAMTS12, a secreted protein, is involved in extracellular matrix (ECM) remodeling, cell signaling, and inflammation. ADAMTS12 facilitates proteolysis by cleaving various substrates such as ECM components, which are vital for cellular signaling and remodeling. Additionally, it modulates cell-matrix interactions, influencing cell adhesion and migration, and plays an important role in the inflammatory processes. Understanding the role of ADAMTS12 offers potential therapeutic insights for targeting fibrosis in progressive diseases.
Clavicle fractures are the most common fractures of the shoulder girdle. Due to the complex sensory innervation of the clavicle, patients' pain scores are high in the postoperative period. Therefore, multimodal regional analgesia techniques provided by the combination of cervical plexus and/or brachial plexus have been successfully applied in the literature. Serratus posterior superior intercostal plane block (SPSIPB) is a plane block that provides anterolateral chest wall analgesia. It provides analgesia between C3 and T10. In this case report, our experience with SPSIPB, which we applied for rescue analgesia in a patient who underwent surgery for a clavicle fracture, is described.
PURPOSE:To reduce the time required for clotting of a blood in the stage of clotting the blood by allowing a cyclic org. compd. of which the two adjacent carbonyl groups are three-dimensionally and substantially on the same plane to exist in the blood. CONSTITUTION:The sepn. of a blood to a serum and blood-clot by a centrifugal sepn. according to this method is accomplished by allowing a cyclic org. compd. which is expressed by the general formula shown in the figure and in which the two adjacent carbonyl groups in said general formula are three-dimensionally and substantially on the same plane to exist in the blood. Such accelerator for blood clotting as the one mentioned above is present in the blood according to the above-mentioned method and therefore the blood clotting factor is quickly activated and the time required for clotting after sampling of the blood in a vessel is considerably reduced and at the same time the sepn. of the serum and the blood-clot is made extremely easy. The proble that the blood-clot component exists mixedly in the separated and drawn sample is thus solved and further the shrinkage of the blood-clot component is substantially accomplished, by which the yield of the serum is considerably increased.
In both phases 100 subjects will perform a gait rehabilitation intervention program (phase 1) and maintenance (phase 2), in which they will employ the use of the robotic walker and virtual reality depending on the group and phase. The evolution of functional clinical parameters will be studied for both groups and phases.
NEW MATERIAL:A compound expressed by formula I {R1 is formula II or III [R3 is halogen, lower alkyl, (substituted) phenyl, etc.; Z is S or O], etc.; R2 is H or lower alkyl}. EXAMPLE:1-(3-Phenyl-5-isoxazolyl)-3-(1-imidazolyl)methylindole hydrochloride. USE:An anticonvulsant. PREPARATION:A compound expressed by formula IV (R4 is halogen, lower alkyl, lower alkoxy, CF3 or CN) is reacted with a compound expressed by formula V to provide a product, which is then reacted with NH2OH and cyclized to afford a compound expressed by formula VI. The resultant compound expressed by formula VI is subsequently halogenated and the resultant product is then reacted with a compound expressed by formula VII to afford the objective compound expressed by formula VIII.
AUY922 will be administered as a weekly infusion at a dose of 70 mg/m2 based on the recommended phase II dose from the phase I study or alternate dose based on the phase I study final results.The drug will be continued until disease progression or unacceptable toxicity. One cycle will be defined as 4 weeks of treatment.
Patients will receive single doses of propranolol (20 mg, oral) and placebo on a randomized study day. Medications will be dummy blinded to the patient and investigators.
Patients will be treated with anakinra, injected SQ daily in a dose of 100mg for 14 days. Before and after this intervention, patients will undergo cardiopulmonary exercise testing (as well as echocardiography, EKG analysis, and serologic analysis). Subjects will be assessed for changes in exercise capacity, as determined by peak oxygen uptake and ventilatory efficiency to CO2 production slope.
PURPOSE: To obtain the a composition useful for preventing diseases of oral cavity, having excellent antifungal activities against dental caries and fungi causing periodontal diseases and improved safety. CONSTITUTION: This composition for oral cavity comprises an extract of carrot with an organic solvent and/or an extract of Alpinia galanga with an organic solvent and the purified. The composition for oral cavity comprises extracted or synthesized caryophyllene oxide. The extract, for example, is obtained by extraction at room temperature or under heating for 1 hour or about one day. The amount of caryophyllene oxide as an active ingredient added to the composition is 0.0001-5wt.%, especially 0.001-3wt.%. The composition is useful as a toothpaste, liquid dentifrice, pasta for oral cavity, gargling tablet and troche.